Trial reportNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2022
A Randomized Pilot of a Tailored Smoking Cessation Quitline Intervention for Individuals Who Smoke and Vape.
Trial report in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 8 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Electronic cigarettes for smoking cessation.The Cochrane database of systematic reviews · 2026Pooled it
- Comparative effects of electronic cigarettes and dual use of electronic and conventional cigarettes on adverse pregnancy outcomes: a systematic review and meta-analysis.BMC public health · 2025Pooled it
- Electronic cigarettes for smoking cessation.The Cochrane database of systematic reviews · 2025Pooled it
- Korean Clinical Practice Guideline of Korean Society for Research on Nicotine and Tobacco (KSRNT) and National Evidence-based Healthcare Collaborating Agency (NECA) on Treatment of Tobacco Use 2024.Journal of Korean medical science · 2025Guideline
- Electronic cigarettes for smoking cessation.The Cochrane database of systematic reviews · 2025Pooled it
- The potential of new nicotine and tobacco products as tools for people who smoke to quit combustible cigarettes - a systematic review of common practices and guidance towards a robust study protocol to measure cessation efficacy.Harm reduction journal · 2024Pooled it
- Electronic cigarettes for smoking cessation.The Cochrane database of systematic reviews · 2024Pooled it
- Electronic cigarettes for smoking cessation.The Cochrane database of systematic reviews · 2022Pooled it
- A Factorial Randomized Clinical Trial of Nicotine Replacement Therapy and Treatment Recommendations to Quit Versus Continue E-cigarettes When Quitting Smoking in Young Adult Dual Users.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025Trial
- Relative Efficacy of an Acceptance and Commitment Therapy-Based Smartphone App with a Standard US Clinical Practice Guidelines-Based App for Smoking Cessation in Dual Users of Combustible and Electronic Cigarettes: Secondary Findings from a Randomized Trial.Substance use & misuse · 2024Trial
- Interest in Quitting and Utilizing Quitline Services Among Long-Term E-Cigarette Users.Substance use & misuse · 2025Article
- E-cigarette cessation and transitions in combusted tobacco smoking status: longitudinal findings from the US FDA PATH Study.Addiction (Abingdon, England) · 2023Article
- Dual Use of Combustible Cigarettes and E-cigarettes: a Narrative Review of Current Evidence.Current addiction reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
introductionAlthough e-cigarettes are not a federally approved tobacco cessation aid in the United States, many smokers use them to quit or cut down on smoking. Tailored behavioral support could improve rates of complete smoking cessation for those individuals. AIMS AND
methodsA novel behavioral treatment to help dual cigarette and e-cigarette users quit smoking was tested in a randomized pilot with a state tobacco quitline. Ninety-six dual users of cigarettes and e-cigarettes were recruited from incoming state quitline callers and randomized to receive enhanced e-cigarette coaching (EEC) or quitline treatment as usual (TAU) to examine EEC feasibility and acceptability. Outcomes at 3 months were treatment satisfaction, engagement, beliefs, and smoking cessation. This pilot was not powered to detect differences in quit rates.
resultsSixty-nine percent responded to the 3-month survey. EEC treatment satisfaction was noninferior to TAU: 93.8% (30/32) of EEC and 73.5% (25/34) of TAU reported being "very satisfied" or "satisfied" with treatment, respectively. EEC participants completed more coaching calls than TAU (M = 3.4 vs. M = 2.7, p = .03), and the majority in both groups elected to receive nicotine replacement therapy (EEC: 100%, TAU: 94%, p = .24). With missing data imputed as smoking, intent-to-treat 7-day point prevalence smoking abstinence rates were 41.3% (19/46) for EEC and 28.0% (14/50) for TAU (p = .20).
conclusionsThe EEC quitline intervention for dual cigarette and e-cigarette users demonstrated high levels of treatment satisfaction and engagement. This pilot was not powered to detect significant differences in smoking cessation; however, cessation rates were promising and warrant evaluation in a fully powered trial. IMPLICATIONS: If this scalable behavioral treatment to help dual cigarette and e-cigarette users quit smoking proves to be effective in a larger trial, quitlines could implement this harm reduction approach to improve outcomes for callers who already use e-cigarettes and are planning to use them while quitting smoking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.